REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer

14 May 2025 05:00:01 By Nasdaq GlobeNewswire

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

07 May 2025 13:02:00 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

30 Apr 2025 13:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

27 Apr 2025 09:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

01 Apr 2025 13:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in April 2025 Investor Conferences

31 Mar 2025 13:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

26 Feb 2025 13:02:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in March 2025 Investor Conferences

24 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

19 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

29 Jan 2025 13:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 13:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

05 Dec 2024 13:05:49 By Nasdaq GlobeNewswire

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

03 Dec 2024 19:38:42 By Nasdaq GlobeNewswire

Revolution Medicines Announces Commencement of Public Offering of Common Stock

02 Dec 2024 13:31:20 By Nasdaq GlobeNewswire

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

02 Dec 2024 04:30:02 By Nasdaq GlobeNewswire

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

27 Nov 2024 13:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

06 Nov 2024 13:02:32 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

05 Nov 2024 06:00:30 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

30 Oct 2024 13:05:23 By Nasdaq GlobeNewswire

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

25 Oct 2024 01:15:00 By Nasdaq GlobeNewswire